A biotechnology company developing a corrective topical protein therapy for dystrophic epidermolysis bullosa (DEB)
Biotech
8 sources · checked 1 time, last 2h ago
The financing includes an initial tranche and additional capital committed subject to specified development milestones.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round | $23M | 2026-11-05 | Viking Global Investors | 7 outlets. #37 in Trending |
8 sources · checked 1 time, last 2h ago [ VERIFIED ] read against 4 of 8 sources The financing includes an initial tranche and additional capital committed subject to specified development milestones. [ BUILT WITH ]·[ SEARCH ]found on a watched publisher·[ SCRAPE ]8 pages read: globenewswire.com, markets.businessinsider.com, biospace.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 4 of 8 sources | ||||